Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses

(2016) Simon Faissner et al.   JOURNAL OF NEUROLOGY

Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies

(2016) Ding Chen et al.   Journal of Clinical Medicine

B Cells and Autoantibodies in Multiple Sclerosis

(2015) Anne-Katrin Pröbstel et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Single Dose of Glycoengineered Anti-CD19 Antibody (MEDI551) Disrupts Experimental Autoimmune Encephalomyelitis by Inhibiting Pathogenic Adaptive Immune Responses in the Bone Marrow and Spinal Cord while Preserving Peripheral Regulatory Mechanisms

(2014) Ding Chen et al.   JOURNAL OF IMMUNOLOGY

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

(2014) P. S. Sorensen et al.   NEUROLOGY

The Plasma Cell Signature in Autoimmune Disease

(2013) Katie Streicher et al.   Arthritis & Rheumatology

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission

(2011) Stephanie Knippenberg et al.   JOURNAL OF NEUROIMMUNOLOGY

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody

(2010) R. Herbst et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

B lymphocytes: how they develop and function

(2008) T. W. LeBien et al.   BLOOD

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE